A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6864018 Following Oral Administration in Asian Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Mar 2017
Price : $35 *
At a glance
- Drugs RO 6864018 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Roche
- 23 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTriald.gov record.
- 14 Oct 2014 Planned End Date changed from 1 Aug 2014 to 1 Nov 2014 as reported by ClinicalTriald.gov.
- 14 Oct 2014 Planned primary completion date changed from 1 Aug 2014 to 1 Nov 2014 as reported by ClinicalTriald.gov.